Skip to main content
. 2015 Sep 29;2(2):153–164. doi: 10.1007/s40744-015-0019-6

Fig. 3.

Fig. 3

Estimated survival functions for months from Corrona RA registry enrollment to initiation of a first use of any RA-directed therapy, b first use of nbDMARDs or steroids, and c first use of nbDMARDs excluding steroids among patients with no history of RA-directed therapy at time of enrollment. KM Kaplan–Meier, nbDMARD non-biologic disease-modifying antirheumatic drug, RA rheumatoid arthritis